Nephronectin promotes breast cancer brain metastatic colonization via its integrin-binding domains by Magnussen, Synnøve Norvoll et al.
1
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12237  | https://doi.org/10.1038/s41598-020-69242-1
www.nature.com/scientificreports
nephronectin promotes 
breast cancer brain metastatic 
colonization via its integrin‑binding 
domains
Synnøve norvoll Magnussen1,2*, Jimita Toraskar3,4, Imola Wilhelm2,5, Janos Hasko2, 
Stine Linn figenschau1, Judit Molnar2, Marit Seppola1, Sonja E. Steigen1,6, 
Tonje S. Steigedal3,4, Elin Hadler‑Olsen1,6,7, Istvan A. Krizbai2,5,8 & Gunbjørg Svineng1,8
this study demonstrates a role for the extracellular matrix protein nephronectin (npnt) in promoting 
experimental breast cancer brain metastasis, possibly through enhanced binding to‑ and migration 
through brain endothelial cells. With the introduction of more targeted breast cancer treatments, a 
prolonged survival has resulted during the last decade. Consequently, an increased number of patients 
develop metastasis in the brain, a challenging organ to treat. We recently reported that NPNT was 
highly expressed in primary breast cancer and associated with unfavourable prognosis. The current 
study addresses our hypothesis that npnt promotes brain metastases through its integrin‑binding 
motifs. SAGE‑sequencing revealed that NPNT was significantly up‑regulated in human breast cancer 
tissue compared to pair‑matched normal breast tissue. Human brain metastatic breast cancers 
expressed both NPNT and its receptor, integrin α8β1. Using an open access repository; BreastMark, 
we found a correlation between high NPNT mRNA levels and poor prognosis for patients with the 
luminal B subtype. The 66cl4 mouse cell line was used for expression of wild‑type and mutant NPNT, 
which is unable to bind α8β1. Using an in vivo model of brain metastatic colonization, 66cl4‑NPNT 
cells showed an increased ability to form metastatic lesions compared to cells with mutant NPNT, 
possibly through reduced endothelial adhesion and transmigration.
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PR  Progesterone receptor
RGD  Arginine-glycine-aspartic acid
rmNPNT  Recombinant mouse nephronectin
TNBC  Triple negative breast cancer
Background
Breast cancer (BC) is a heterogeneous disease that can be divided into four main molecular subtypes: luminal 
A, luminal B, basal-like, also known as triple-negative breast cancer (TNBC), and human epidermal growth 
factor receptor (HER2)—enriched1. The different subtypes are associated with differences in outcome and are 
eligible for selected treatments according to the expression of the estrogen receptor (ER), progesterone receptor 
(PR) and HER2. TNBC lacks the expression of all three receptors and the major adjuvant treatment available is 
 chemotherapy1,2. The luminal subtypes constitute more than half of all BCs and have a better outcome due to 
the success of endocrine therapies. Metastatic sites include the axillary nodes and distant organs such as lung, 
bone, liver and  brain3. More than 25% of all BC patients develop brain metastasis at some  point4, a terminal 
condition with very few treatment options and a median life expectancy of 15 months upon  diagnosis3. Due to 
improved systemic treatment of recurrent disease, BC patients have increased life expectancy. However, although 
many drugs may control extracranial metastasis, they often have little or no effect on intracranial  metastasis5. 
This calls for new approaches in the treatment of brain metastasis. Not all cancer types tend to spread to the 
 brain6 and it is still not fully understood why BC cells have an increased ability to home to and grow in the brain 
 microenvironment4,7. For cancer cells to reach the brain parenchyma, they have to cross the tightly regulated 
blood–brain-barrier (BBB) that consists of endothelial cells, a vascular basement membrane, pericytes and astro-
cytic end-feet. The brain endothelial cells are non-fenestrated, have restricted pinocytosis and are continuous, 
linked together by tight junctions. They are hence the brain’s first line of defence against metastatic cancer  cells4. 
Many brain metastases are resistant to chemotherapy and targeted drugs, possibly because the brain microenvi-
ronment can function as a sanctuary site, protecting the metastatic cancer cells and supporting tumour  growth4,5. 
This calls for the development of new drugs that can treat or even inhibit the establishment of brain metastasis.
Human nephronectin (NPNT) is a 62 kDa secreted protein that shares 88% amino acid sequence identity 
with mouse  NPNT8. It contains five EGF-like domains, a linker region harbouring two integrin-binding motifs, 
and a MAM (meprin, A-5 protein, and receptor protein-tyrosine phosphatase mu)  domain9,10. The integrin-
binding motifs include a common RGD-binding motif and an LFEIFEIER-enhancer  motif9,11. All RGD-binding 
integrins can potentially recognize the RGD-sequence, and so far, NPNT binding to integrins α8β1, αVβ3, 
αVβ5, αVβ6, α4β7 and α5β1 has been  demonstrated10. However, the LFEIFEIER-motif is thus far only reported 
to be involved in binding to integrin α8β111,12 and NPNT functions as a crucial α8β1-ligand during embryonic 
kidney  development10,13. In the development of zebrafish heart, NPNT also plays an important role, but not 
through α8β1-binding, as this receptor is absent in the  tissue14. This indicates that NPNT also signals through 
additional receptors in vivo. In more recent publications, NPNT expression has been linked to both stem cell 
 differentiation15,16 and  angiogenesis17. Using a mouse model of spontaneous BC metastasis, it was previously 
shown that BC cells with high metastatic potential expressed more NPNT compared to low metastatic BC  cells18. 
Knock down of NPNT in highly metastatic cells caused a significant reduction in metastasis to the lungs, liver 
and  spine18. More recently, we demonstrated that NPNT promotes lung metastasis in mice through its integrin-
binding  motifs19. A comprehensive study of NPNT protein expression patterns in human primary BC revealed 
NPNT as a potential prognostic marker for  BC19. Together these results indicate an important role for NPNT in 
BC metastasis. Brain metastases usually develop at later stages of tumour progression, and were not specifically 
analysed in previous  studies18,19. We hypothesize that NPNT also promotes BC brain metastasis, and the aim of 
the current study was therefore to assess the role of NPNT in the establishment of brain metastasis.
Results
NPNT transcript is up‑regulated in human BC and linked to poor prognosis. To investigate 
whether NPNT expression was dysregulated in BC, we performed deep sequencing of human tumour tissue and 
adjacent non-cancerous breast tissue from 22 patients. Pooled RNA from tumour tissue was compared to pooled 
RNA from pair-matched normal tissue. A total of 1,323 genes were differentially expressed: 613 up-regulated 
and 710 down-regulated. The exhaustive list of genes is presented in Supplementary Table S1. NPNT was upreg-
ulated 3.63 fold (p = 2.58E−12) in tumour tissue compared to normal breast tissue, indicating a dysregulation 
of NPNT gene expression in BC. No change was detected in the levels of integrin subunits α8, αV, β1, β3 or β5. 
To verify the results from the deep sequencing, RT-qPCR was performed on RNA extracted from each tumour 
sample and the pair-matched normal tissue using NPNT specific primers. An increase in NPNT expression was 
observed in 21 out of 22 samples (Fig. 1a). Using the Pam50  classifier20 and the BreastMark  database21, no asso-
ciation was found between high NPNT expression and survival, hazard ratio 0.8678 (0.7235–1.041) (Fig. 1b). 
There was however, a significant association between elevated NPNT levels and poor outcome in patients with 
the luminal B subtype, hazard ratio 1.46 (1.072–1.989) (Fig. 1c).
Resections from five patients with BC brain metastasis were analysed by RNA Scope in situ hybridization 
(ISH) for the presence of NPNT mRNA. Positive and negative controls can be viewed in Supplementary file 1 
and Supplementary Fig. S1. As a proof of concept, NPNT mRNA was detected in all of the samples (Fig. 1d), 
with three samples showing areas of clear positive staining and two showing weak focal staining. For the sam-
ple in Fig. 1d, showing strong staining, the surrounding tumour stroma was negative for NPNT. IHC analyses 
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Figure 1.  NPNT mRNA is expressed in human BC and connected to poor prognosis for the luminal B subtype. 
Expression and distribution of NPNT and integrin α8β1 in human primary BC and brain metastases. (a) Fresh 
BC tissue and pair-matched non-cancer tissue from 22 patients was analysed for the presence of NPNT mRNA 
by RT-qPCR. The values are given as fold expression in cancer tissue compared to non-cancer tissue, which is 
set to 1 for each patient. The BC subtype is given for every patient. (b) Kaplan–Meier survival plots showing 
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The presence of the NPNT-binding integrin subunit α8 (Itgα8) was analysed by IHC in the human BC brain 
metastases. Itgα8 was present in the same areas that showed NPNT expression (Fig. 1g). Positive staining for 
the α8 subunit indicates the presence of the α8β1 receptor. These results show that the brain metastatic BC cells 
express both NPNT and integrin α8β1.
NPNT is upregulated in mouse models of BC. To assess whether mouse models of BC could reca-
pitulate the NPNT expression observed in human BC tissue, we analysed NPNT protein levels by IHC on tissue 
sections from either MMTV-PyMT mice, a mouse model that closely mimics the development of human  BC22, 
wild-type female FVB mice, or pregnant FVB mice. Normal mammary glands from FVB mice showed no NPNT 
staining whereas glands from pregnant FVB mice showed weak staining. MMTV-PyMT BC tissue was clearly 
positive (Fig. 2a). Three human BC cell lines with different receptor status were used to create xenograft tumours 
in mice: MCF-7 (luminal A), SK-BR-3 (HER2+) and BT474 (luminal B)23. NPNT was expressed in all tumours 
(Fig. 2b, c), with highest expression in the BT474 tumours (Fig. 2c).
The expression and distribution of Npnt and the proposed NPNT-interacting integrins in the brain were 
retrieved from the Mouse Allen Brain  Atlas24 (2004 Allen Institute for Brain Science. Allen Mouse Brain Atlas. 
Available from: https ://mouse .brain -map.org/), an open database generated by the Allen Institute (https ://www.
allen insti tute.org/). ISH showed generally low Npnt expression in the mouse brain, with stronger expression along 
the granule cell layer of the dentate gyrus, an area known to contain stem/progenitor  cells25 (Supplementary 
Fig. S2). Staining for integrin subunit α8 mRNA was mostly negative in adult mouse brain tissues (results not 
shown). The RGD-binding integrins αVβ3 and αVβ5 are expressed by many endothelial cells in the body and 
are potential receptors for  NPNT10. The mRNA of the αV subunit was distributed evenly throughout the brain 
tissue (Supplementary Fig. S2), with strong expression in the pyramidal layer of the piriform area of the cerebral 
cortex (Supplementary Fig. S2). Taken together, these results show that NPNT is expressed in different mouse 
models of BC, and only in restricted regions of the brain.
NPNT co‑localizes with integrin α8β1 on the cell surface of mouse BC cells. The mouse BC 
cell line 66cl4 was chosen for further studies due to low endogenous expression of NPNT, expression of inte-
grin α8β1 (Supplementary Fig. S3), and a weak metastatic potential in vivo, preferentially metastasising to the 
 lungs18,19. This cell line was therefore an optimal choice for over-expression of either wild type NPNT (66cl4-
NPNT), or NPNT where the two known integrin-binding sites (RGD and LFEIFEIER-enhancer site) were 
mutated (66cl4-RGE-AIA). As a control 66cl4 cells were stably transfected with an empty vector (66cl4-EV)19. 
More detailed information and expression data can be viewed in Supplementary file 1 and Supplementary 
Fig. S3. To test whether NPNT could locate to the cell surface of 66cl4 cells, we analysed the distribution of 
NPNT, integrin αVβ3 and integrin subunit α8 by immunofluorescence (Fig. 3). The α8 subunit is believed to 
exclusively heterodimerize with the β1 integrin  subunit26,27, hence the staining represents α8β1. The control cells, 
66cl4-EV, showed no expression of NPNT, and focal distribution of α8β1 (Fig. 3a). On 66cl4-NPNT cells NPNT 
co-localized with α8β1 (Fig.  3b). 66cl4-NPNT cells showed no expression of integrin αVβ3 (Fig.  3c). When 
recombinant mouse NPNT (rmNPNT) was exogenously supplied to 66cl4-EV cells, co-localization of integrin 
α8β1 and rmNPNT was observed (Fig. 3d). However, in cells expressing NPNT mutated in the integrin binding 
sites, all co-localization with α8β1 was lost (Fig. 3e). Controls showed no autofluorescence and no unspesific 
binding of the secondary antibody (Fig. 3f). Taken together, these results demonstrate that extracellular NPNT 
can co-localize with integrin α8β1.
npnt and its integrin‑binding sites enhance the rate of brain metastatic colonization in 
mice. As a model system for BC brain metastasis, the mCherry expressing 66cl4 cells were used to explore 
the role of NPNT and integrin interaction during the metastatic process. To assess the importance of NPNT 
in establishing BC brain metastasis in vivo, a mouse model for experimental brain metastasis was  used28. The 
66cl4-EV, -NPNT and -RGE-AIA cells were injected into the carotid artery to assess whether cells were able to 
establish brain metastases. As a control, three mice were injected with buffer only. Metastatic cells were identi-
fied using antibodies towards the overexpressed mCherry  protein18. Controls showed that the mCherry antibody 
was specific (Fig. 4a). All cell lines established brain metastases within seven days, where the metastatic lesions 
presented as four different phenotypes (Fig. 4b): single cells (I), cells surrounding vessels/vessel co-option (II), 
vessel outgrowth (III) and established metastatic tumour (IV). Compared to the 66cl4-EV cells, the 66cl4-NPNT 
the probability for disease specific survival based on high/low (median cut-off) expression levels of NPNT 
mRNA in BC (all subtypes) and related to months after diagnosis. Data was collected using the publicly available 
database BreastMark. N = 876, number of events = 466. (c) Kaplan–Meier survival plots showing the probability 
for disease specific survival based on high/low expression levels of NPNT mRNA (median cut-off) in luminal B 
subtype of BC and related to months after diagnosis. Data was collected using the publicly available BreastMark 
database. p < 0.05 was considered statistically significant. N = 323, number of events = 188. (d, e) Tissue sections 
of BC brain metastasis (N = 5) were analysed by RNA Scope ISH for the presence of NPNT mRNA. Each brown 
dot indicates the presence of NPNT mRNA. (b) Representative image of metastasis with high levels of NPNT 
mRNA. The tumour stroma was negative; T = tumour, S = stroma. Counterstained with haematoxylin. (e–g) 
Tissue sections of the same region from one BC brain metastasis showing positive brown staining for NPNT 
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cells on average established more of lesion type I + II (Fig. 4c). Mutating the RGD and EIE integrin-binding sites 
drastically reduced the amount of lesion I + II. More advanced lesions (lesion III and IV) were less common, 
but similarly as for the smaller lesions, 66cl4-NPNT cells established 50 lesions in total, while 66cl4-EV cells 
established 35 lesions. The 66cl4-RGE-AIA cells established only 12 lesions in total. Buffer injected controls 
had no lesions. Taken together, these results indicate that NPNT promotes BC brain metastasis in an integrin-
dependent manner.
NPNT does not increase the mean vessel density (MVD). NPNT was recently linked to  angiogenesis17. 
To investigate whether 66cl4 cells expressing NPNT influenced angiogenesis in our brain metastasis model, 
brain tissue sections were IHC stained for the blood vessel marker, CD31 (Supplementary Fig. S4). We found 
no differences in mean vessel density (MVD) and mean vessel size (MVS) between mice injected with the dif-
ferent 66cl4 clones (Supplementary Fig. S4). However, the MVS tended to increase in the brains of all the cancer 
cell injected mice compared to the buffer-injected mice (Supplementary Fig.  S4), but the difference was not 
statistically significant. Transvascular pillars form during intussusceptive angiogenesis; a process more common 
Figure 2.  NPNT protein is expressed in mouse model systems of BC. NPNT protein is present in MMTV-
PyMT transgenic mice that naturally develop BC, and human cancer cells xenografts. (a) Normal FVB mouse 
breast tissue (14 weeks, N = 2), breast tissue from pregnant FVB mice (12 weeks, N = 2) and fully developed 
BC mouse tissues (14 weeks, N = 2) were analysed for the presence of NPNT protein expression by IHC. (b) 
Human BC cell lines MCF-7, SK-BR-3 and BT474, were injected subcutaneously to create xenograft tumours 
(N = 2). Tumours were harvested, fixed, sectioned and analysed by IHC for the presence of NPNT protein. 
Controls: primary antibody was omitted. (c) ImmunoRatio (https ://153.1.200.58:8080/immun orati o/) was used 
to quantify the staining intensities in the IHC stained human xenograft tumours. 15 images were recorded per 
tumour (n = 30), p = 0.0001. Information on the cell line’s receptor status was gathered from  reference23.
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Figure 3.  NPNT co-localizes with integrin α8β1 on the 66cl4 cell surface. Immunofluorescent staining of 
NPNT (green), integrin subunit α8 (red) or integrin αVβ3 (red) in 66cl4 control cells or 66cl4 cells expressing 
either wild-type NPNT or a mutated version of NPNT (RGE-AIA). Nuclei are stained blue with dapi. (a) 
66cl4-EV cells double stained for NPNT and integrin subunit α8. (b) 66cl4-NPNT cells double stained for 
NPNT and integrin subunit α8. (c) 66cl4-NPNT cells double stained for NPNT and integrin αVβ3.(d) 66cl4-EV 
cells with exogenously added rmNPNT and double stained for NPNT and integrin subunit α8. (e) 66cl4-RGE-
AIA cells double stained for NPNT and integrin subunit α8. (f) Controls where 66cl4-NPNT cells were treated 
according to the same protocol, but with both primary antibodies omitted.
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Figure 4.  NPNT and its integrin-binding sites enhance the rate of brain metastatic colonization in mice. IHC 
analysis of mouse brains containing metastatic 66cl4 cells using the anti-mCherry antibody. Positive staining is 
seen as brown colour. Counterstained with haematoxylin. (aI) BALB/c mince injected with mCherry positive 
tumour cells. IHC analysis were performed as usual, omitting the primary antibody. (aII) Buffer injected mice. 
(aIII) BALB/C mice injected with mCherry negative tumour cells. (b) The 66cl4 cells gave four distinct growth 
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in brain metastasis where vessels increase in  size4,29. Structures resembling transvascular pillars were observed 
(Supplementary Fig. S4) which could explain the increased MVS.
NPNT triggers intracellular signalling in brain endothelial cells. To assess whether NPNT could 
influence intracellular signalling in brain endothelial cells as a part of the metastatic process, bEND.3 cells were 
seeded onto an rmNPNT coated surface. A protein of approx. 70 kDa showed an increase in tyrosine phos-
phorylation after three hours of incubation (Fig. 5a). The phosphorylation increased with time and was most 
prominent after 24 h. As the bEND.3 cells do not express integrin α8β1 (Supplementary Fig. S3), NPNT must 
therefore bind to another unidentified receptor. To assess which signalling pathways were involved, the cells were 
analysed using Proteome Profiler (Fig. 5b). As a non-adhesion control, bEND.3 cells were seeded on pluronic-
coated wells. The results showed that phosphorylation of extracellular signal-regulated kinase 1 (ERK1) and 
ERK2 (T202/Y204, T185/Y187) were strongly up-regulated (Fig. 5b, green box), and phosphorylation of AMP-
activated protein kinase (AMPKα1; T183) was strongly down-regulated (Fig. 5b, red box). Also heat-shock pro-
tein 60 (HSP60) was strongly upregulated (Fig. 5b, green box). Some proteins showed more inconsistent results, 
with no change in one run and up/down regulations in the other. These are also marked in Fig. 5b and included 
mitogen stimulated kinase 1 (MSK1) and MSK2 (S376/S360), CREB (S133), signal transducer and activator 
of transcription 2 (STAT2; Y689) and STAT3 (Y705). Taken together, these results show that in response to 
rmNPNT, several signalling pathways are activated in the endothelial cells, as shown on the tyrosine phospho-
rylation on Western blots and on the Proteome Profiler. This suggests that the endothelial cells are equipped with 
currently unidentified NPNT receptors.
the integrin‑binding sites of npnt are important for adhesion and transmigration through 
endothelial cells. Through expression of integrin α8β1 (Supplementary Fig. S3) and possibly other inte-
grins, the 66cl4 cells adhere strongly to recombinant NPNT (Supplementary Fig. S3), as we have also shown 
 previously19. To assess the role of the integrin-binding motifs in the adhesion process, we produced and purified 
wild-type recombinant mouse NPNT (WT-rmNPNT) and NPNT where both the RGD- and EIE-motifs were 
mutated (mutant-rmNPNT). 66cl4-EV cells seeded on protein-coated wells showed increased ability to adhere 
to WT- compared to mutant-rmNPNT (Fig.  5c). Additionally, adhesion to WT-rmNPNT was significantly 
reduced in the presence of RGD peptide (Fig. 5d), as also shown previously when coating with a commercially 
available  rmNPNT19. This indicates the involvement of both the RGD- and EIE- integrin-binding motifs in the 
adhesion process.
We next assessed the role of NPNT in the adhesion of 66cl4 cells to primary mouse brain endothelial cells 
(MBECs). For this purpose, a well-documented in vitro attachment model was  used30,31. As shown in Fig. 5e, 
66cl4-NPNT cells showed increased ability to attach to the MBEC monolayers compared to the 66cl4-EV and 
66cl4-RGD-AIA cells. When the 66cl4 cells were seeded onto the mouse brain endothelial cell line bEND.3 no 
significant differences were observed (Fig. 5f). This could be explained by the lack of integrin α8β1 expression 
by the bEND.3 cells (Supplementary Fig. S3).
To analyse whether NPNT expression in BC cells could have an effect on their ability to migrate through 
MBEC monolayers, we used an in vitro model of  transmigration30,31. As shown in Fig. 5g, 66cl4-NPNT cells 
had an increased ability to migrate through the MBEC monolayers compared to the 66cl4-EV and 66cl4-RGD-
AIA cells. Taken together, these results show that the integrin-binding sites of NPNT are not only important 
for binding to primary endothelial cells, but also for the transmigratory process, implicating a functional role 
of NPNT in metastasis.
Discussion
Today, better treatment options for BC patients have improved the outcome and prolonged patient survival. 
As a consequence, the incidence of BC brain metastases have  increased32,33. Hence, BC brain metastasis is a 
growing clinical challenge that needs to be addressed. Our functional studies demonstrate a role for NPNT in 
establishing BC brain metastases.
In a panel of mouse BC cell lines, NPNT was previously identified as one of the genes associated with 
increased metastatic propensity. NPNT knock-down also resulted in diminished spontaneous metastasis to the 
lungs, liver and spine in a mouse BC  model18. During kidney development in mice, NPNT is known to bind 
integrin α8β1, triggering epithelial cells of the ureteric bud to invade the metanephric  mesenchyme10,13. NPNT 
has also been linked to stem cell  differentiation15,16 and is expressed in areas of the mouse brain known to harbour 
stem/progenitor cells (Supplementary Fig. S2). NPNT, and its potential downstream effects, is therefore intriguing 
with regards to metastasis. More recently, we reported the involvement of the NPNT integrin-binding motifs in 
enhancing BC lung metastasis in  mice19. NPNT was also found to promote anchorage independent growth and 
survival, providing cancer cells with a growth  benefit19,34. These results could indicate a functional role for NPNT 
in metastasis. Other ECM proteins, such as tenacin C (TNC), have also been reported to play an important role 
in the early steps of metastatic seeding of the lungs. However, TNC had no effect on the seeding of BC cells in 
the brain, suggesting that other ECM proteins could have a role in brain  metastasis35.
patterns in the brain: single cells (I), vessel co-option/surrounding vessels (II), vessel outgrowth (III) and 
established tumour (IV). (c) Lesion type I and II were scored in hot-spots and average values are shown in the 
graph. p = 0.013.
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Figure 5.  The integrin-binding sites of NPNT are important for adhesion. (a) bEND.3 cells were seeded 
onto rmNPNT- or pluronic coated surfaces for 0, 1, 3, 5 or 24 h. Cell lysates were harvested and analysed by 
Western blotting for tyrosine phosphorylation. (b) bEND.3 cells were seeded onto rmNPNT- or Pluronic coated 
surfaces for 3 h. Harvested cell lysates were analysed for specific tyrosine phosphorylated proteins using the 
Proteome Profiler antibody array (human Phospho-kinase Array). (c) Adhesion of 66cl4-EV cells to rmNPNT 
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We postulated a role for NPNT in establishing BC brain metastasis, an organ that shows selectivity towards 
metastatic cells, and where as much as 30% of all metastases originate from BC . With regards to Paget’s “seed 
and soil” hypothesis , the brain may therefore be a very particular kind of soil. In our study, we found that 21 out 
of 22 patients had up-regulated expression of NPNT mRNA in primary human BC compared to pair-matched 
non-cancerous breast tissue. In addition, high levels of NPNT transcript were linked to poor prognosis for the 
luminal B subtype, and both NPNT and integrin α8β1 were found to be expressed in human BC brain metastases. 
When wild-type NPNT was overexpressed in mouse BC cells, an increased number of metastatic lesions was 
observed in the brain when cells were injected into the carotid artery (Fig. 4). This is in line with our previous 
results showing that NPNT enhances metastasis to the lungs via its integrin-binding  motifs19. Mutating the 
integrin-binding motifs of NPNT stongly reduced the cell’s ability to establish metastatic lesions in the brain 
(Fig. 4), and  lungs19. Although in vivo studies resulted in the same tendencies as previously  published19, we now 
observed that the double mutant (66cl4-RGE-AIA) established fewer metastatic lesions than the control cell line 
(66cl4-EV). This finding was unexpected. This could reflect a difference in methodology between the two studies, 
but could also be a tissue specific finding. Though more work would be needed, it is tempting to speculate the 
the double mutant somehow sequesters cell surface receptors and functions as an inhibitor of brain metastasis. 
The fact that NPNT only resulted in a prognostic value for the luminal B subtype, although up-regulated in most 
breast cancers, could also indicate that the combination of the molecular profile of the BC cells and NPNT play 
a part in the metastatic process. In the current study, we additionally show that NPNT is involved in adhesion 
to and migration through the brain endothelial cells (Fig. 5e, g). These results are intriguing as they indicate 
that a cell surface localisation of NPNT is important during the metastatic process. NPNT contains five EGF-
like domains, a linker region with two integrin-binding motifs, and a MAM-domain9,10. Three of the EGF-like 
repeats are calcium-binding, and such EGF-repeats are known to be involved in protein–protein  interactions36. 
The EGF-like repeats of NPNT are also reported to bind chondroitin sulfate E (CS-E), which is expressed in 
brain, kidney, cartilage and hair  follicles37. The EGF-like repeats may also possibly bind  EGFR15,17. The NPNT 
linker region can potentially bind all RGD-recognising integrins, where NPNT is reported to bind integrins 
αVβ3, αVβ5, αVβ6, α4β7, α5β1 and α8β110. MAM-domains are evolutionarily conserved and thought to con-
vey an adhesive  function38. The MAM domain of NPNT was reported to bind heparan sulphate proteoglycans 
(HSPGs)/heparin37 and the basement membrane proteins QBRICK, Fras1 and  Frem239. The MAM domain is 
also postulated to be involved in NPNT dimerization and  tetramerization11. Dimers or tetramers of NPNT might 
bind several different receptors at once, offering a potential mechanism of action. Further studies are needed to 
reveal the exact receptors involved in NPNT-binding in brain endothelial cells. Interestingly, both NPNT and 
α8β1 were expressed in the human BC brain metastases in a similar pattern and intensity, indicating that these 
proteins might be employed also by human BC cells to enhance their ability to grow in the brain microenviron-
ment. Others have reported that expression of α8β1 in BC cells increases their  migration40, and expression of 
NPNT increases  metastasis18.
Exosomes are secreted small extracellular vesicles that can facilitate bidirectional cell–cell communication, 
but are also implicated in creating a pre-metastatic niche. Cargo from BC-derived exosomes has been found in 
lungs, liver, bone and brain, whilst colorectal cancer-derived exosomes primarly home to the  liver41. Interestingly, 
in our recent publications we show that 66cl4 cells concentrates truncated versions of NPNT into  exosomes19,42, 
which could potentially create a favourable microenvironment in the brain during metastasis.
While exosomes could be important in NPNT transmission and thus metastasis to the brain, the signalling 
casades introduced by NPNT in the brain are largely unknown. When brain endothelial cells were seeded on 
rmNPNT, phosphorylation of ERK1/2 was strongly up-regulated and phosphorylation of AMPK1α was strongly 
down-regulated (Fig. 5b). AMPKs are guardians of cellular energy and are “switched on” when cells are under 
metabolic  stress43 or when released from ECM anchorage, which leads to increased autophagy through regula-
tion of mammalian target of rapamycin complex 1 (mTORC1)44. Based on our experiments, NPNT seems to 
counteract this metabolic stress signal by down-regulating the phosphorylation of AMPKα1. When phosphoryl-
ated, active AMPK inhibits cell growth and proliferation and promotes cell polarity through phosphorylation 
of p53, and pharmacological activation of AMPK inhibits cancer cell growth. AMPK is therefore suggested to 
be an “energy checkpoint” that delays progress through the cell cycle if energy is  low43. Active AMPK is also 
involved in maintaining cell polarity, especially in epithelial  cells43. Metformin is a widely used pharmaceutical 
was analysed by real-time cell analysis using the xCELLigence system. The experiments were performed at 
least twice with similar results and with two technical replicates per run. Impedance created by adhering cells 
gave the arbitrary “cell index” value that is proportional to the amount of adhered cells. Adhesion was recorded 
every 15 min for 12 h. Wells were coated with either 3% BSA as a negative control or 10 μg purified wild-type 
rmNPNT (Wild-type) or rmNPNT mutated in the integrin-binding sites (Mutant). Error bars show the pooled 
standard deviation. (d) Wells were coated with 10 μg purified wild-type rmNPNT. Adhesion of 66cl4-EV cells 
in the presence of RGD-blocking peptide or scrambled negative control peptide. p = 0.019. (e) 66cl4 cells were 
seeded onto a confluent monolayer of MBECs. After three hours, non-adherent cells were washed off and 
adherent cells were counted. Fold differences between the cells is shown in the graph (N = 2, n = 3). p = 0.013. 
(f) 66cl4 cells were seeded onto a confluent monolayer of bEND.3 cells. After three hours, non-adherent cells 
were washed off and adherent cells were counted. Fold differences between the cells is shown in the graph 
(N = 3, n = 3). p = NS. (g) 66cl4 cells were seeded onto a confluent monolayer of MBECs. Transmigration of 66cl4 
cells was followed by imaging every 5 min for 24 h. Every cell that transmigrated through the monolayer was 
recorded and fold differences between the cells is presented in the graph (N = 3, n = 3), p = 0.044.
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for diabetes type 2 and it activates AMPK. Interestingly, an epidemiological study on metformin use showed a 
significant reduction in the incidence of different types of  cancer45.
conclusions
In conclusion, we demonstrate an involvement of NPNT in promoting brain metastasis. Our analyses show 
that NPNT is overexpressed in primary BC, and also present in BC brain metastasis, where it is located in the 
same areas as its receptor, integrin α8β1. Furthermore, NPNT is also linked to poor prognosis for the luminal 
B subtype. We also show that the integrin-binding motifs of NPNT are important for BC cell adhesion to- and 
migration through brain endothelial cells. Additionally, NPNT triggered several intracellular signalling pathways 
in the endothelial cells known to be involved in proliferation, differentiation, growth and development. Mouse 
BC cells overexpressing NPNT showed increased ability to establish brain metastases in vivo, an ability that was 
lost when the integrin-binding motifs were mutated. This indicates an important role of the integrin-binding 
motifs in establishing brain metastasis with possible implications for prognosis. Breast cancer brain metastasis 
is an increasing clinical challenge that needs to be met, where NPNT and its binding partners could represent 
novel drug targets, inhibiting brain metastasis in high risk patients before it even occurs.
Methods
RNA extraction and SAGE‑sequencing. Tumor and paired normal tissue samples for SAGE library 
preparations were collected from 23 patients treated at UNN (Tromsø, Norway). RNA for SAGE-sequencing was 
extracted using RNeasy Fibrous Tissue Mini Kit (74704, Qiagen) in addition to Trizol reagent (15596026, Ther-
moFisher Scientific) according to manufacturer’s protocol. SAGE libraries were prepared following the SOLiD 
SAGE Kit with Barcoding Adaptor Module Guide (4452811, ThermoFisher Scientific) according to the supplier’s 
recommendations. Sequencing was performed using SOLiD 5500xl sequencer at the Nord University (Bodø, 
Norway). Differential expression analyses were performed by the DESeq2 package with a FDR cutoff of 0.05 as 
previously described in  detail46. The data that support the findings of this study are available from Figenschau 
et al.46.
Reverse transcriptase quantitative PCR (RT‑qPCR). RT-qPCR was performed as previously 
 described47 with minor changes to the protocol as follows; analysis was performed using the LightCycler (Roche, 
Mannheim, Germany), and target cDNA was amplified through 40 cycles in a 20 μl qPCR mix (FastStart Essen-
tial DNA Green Master, Roche Diagnostics GmbH, Mannheim, Germany) containing 10  μM primer mix 
(primer sequences: see Supplementary file 1). Primer efficiencies were all between 96 and 100%. Samples were 
normalized against the geometric mean of three reference genes: EF1a, Hprt and β-actin.
Cell lines. The mouse BC cell line 66cl4 (PRID: CVCL_9721) with stable expression of mCherry and NPNT 
has previously been  described19. The 66cl4 cells were cultured in 1× Dulbecco’s Modified Eagles Medium 
(DMEM) + GlutaMAX (Gibco, Life Technology, Paisley, UK) containing 10% Fetal Bovine Serum (FBS) (PAN 
Biotech, Aidenbach, Germany). Human BC cell lines were cultured in RPMI-1640-HEPES containing 10% 
FBS, 50 IU/ml penicillin G and 50 μg/ml streptomycin sulfate (SK-BR-3; RRID: CVCL_0033 and BT474; PRID: 
CVCL_0179, ATCC) or α-MEM containing 10% FCS, 1 mM pyruvate, and 100 IU/ml insulin (MCF-7; PRID: 
CVCL_0031, ATCC). Cells were maintained in culture for no more than 4–6 weeks. Mouse brain endothelial 
cells, bEND.3 (PRID: CVCL_0170), were cultured in DMEM with 10% FBS (Biowest, Nuaillé, France). Cells 
were routinely tested for mycoplasma using Mycoalert mycoplasma detection kit (Cat: LT07-218, Cambrex).
Experimental brain metastasis model. BALB/c mice were bred in-house and eight-ten week old 
females were selected for intracarotid injections, as previously  described48. Experimental brain metastases were 
established by injecting 66cl4 (1.0 × 106) cells into the right carotid artery of 8–10 week old female BALB/c mice 
(N = 5/group). Control mice were either subjected to the same procedure, but with only buffer injected (N = 3), 
or were not injected (N = 2). On day 7, mice were anaesthesized and transcardially perfused with PBS followed 
by 4% paraformaldehyde (PFA). Brains were removed and additionally immersion fixed in PFA overnight at 
4 °C. Further details of the procedure can be found in Supplementary file 1.
Immunohistochemistry (IHC). Tissues were obtained, fixed and sectioned as described in Supplementary 
file 1. Details about the IHC procedure and antibodies used are summarized in Table 1. In short, deparaffinised 
tissue sections were subjected to antigen retrieval, endogenous peroxidase blocking with  H2O2, and blocking 
(Table 1). All primary antibodies were incubated at 4  °C overnight. Detection was performed using labelled 
polymer-HRP anti rabbit kit (Cat: K4011, Dako, Glostrup, Denmark) following the manufacturer’s instructions. 
More detailed information about the primary antibodies used can be found in Supplementary file 1. Buffers 
used: Tris-EDTA (10 mM Tris Base, 1 mM EDTA, 0.05% Tween 20, pH 9.0), 10 mM citrate buffer pH 6.0, normal 
goat serum in PBS (Cat: X0907, Dako, Glostrup, Denmark). Images were recorded using the Leica Application 
Suite (LAS version 3.7.0) from Leica Microsystems (Heerburg, Switzerland). For details on scoring methods, 
please view Supplementary file 1.
RNA Scope in situ hybridization (ISH). Deparaffinised FFPE tissue sections were treated according to 
the RNA Scope protocol recommendations (RNA scope 2.5 HD reagent kit-brown, Cat: 322,300, Advanced Cell 
Diagnostics, Milano, Italy). Probes used: Hs-NPNT, Hs-UBC (positive control) and DapB (negative control). 
Details are summarized in Supplementary file 1.
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Immunofluorescence (IF). 66cl4 cells were grown on chambered coverglass (Thermoscientific) for 48 h 
and fixed with 4% paraformaldehyde. Non-permeabilized cells were blocked with 4% normal goat serum in 
PBS. Cells were stained using anti-NPNT (PAB8467, Abnova) (1:150) and integrin specific primary antibodies; 
Integrin α8 (MAB6194, RD systems) (1:150), Integrin αvβ3 (78289, Abcam). Double immunofluorescence was 
achieved using Alexa 488 (1A32731, Life technologies) (1:1,000) and Alexa 647 (A32728, Life technologies) 
(1:1,000). Nuclear staining was performed using Hoechst 33342 (C10337, Life technologies). Fixed cells were 
imaged using a Zeiss LSM 510 META microscope equipped with a 63×/1.45 oil immersion objective. Images are 
representative of three independent experiments.
Recombinant mouse NPNT (rmNPNT). The mouse NPNT gene was cloned as either wild-type or 
mutated in two integrin-binding sites (RGD to RGE and EIE to AIA), V5- and His-tagged, and expressed in 
Sf9 and HighFive insect cells (Invitrogen, Carlsbad, CA). RmNPNT was purified using Talon Superflow cobalt 
columns (GE Healthcare, Uppsala, Sweden) and presence of protein was verified by Western blot and mass spec-
trometry (results not shown). For detailed procedure, see Supplementary file 1.
Real‑time cell analysis (RTCA) of adhesion. A detailed description of the procedure using the xCELLi-
gence system (ACEA Biosciences Inc, San Diego, CA) for adhesion was recently published  elsewhere47. E-Plates 
were coated with either purchased rmNPNT (Cat: 4,298-NP-050, RD Systems, Minneapolis, MN) or purified 
wild-type rmNPNT (wt) or mutated rmNPNT (mutant). Blocking was performed using 3% BSA, one hour 
37 °C. 66cl4-EV cells were detached using 1 mM EDTA and seeded in serum-free medium + /− inhibitory RGD-
peptides (Cat: H-1346, H-Gly-Arg-Gly-Asp-OH) or scrambled peptides (Cat: H-3166, H-Gly-Arg-Gly-Glu-Ser-
OH Trifluoroacetate) at 0.5 mg/ml (Bachem AG, Bubendorf, Switzerland). The arbitrary “cell index” value is 
proportional to number of attached cells.
Primary mouse brain endothelial cells (MBECs) for adhesion and transmigration experi‑
ments. Primary MBECs were isolated from female BALB/c mice (bred in house) according to optimized and 
established protocols as previously  described49,50. A detailed isolation procedure is described in Supplementary 
file 1. Adhesion and transmigration experiments were performed as previously  described30. In short, isolated 
MBECs were cultured to confluence. The 66cl4 cells were seeded onto the MBEC monolayer and either incu-
bated 3 h for adhesion or 24 h for transmigration experiments. The experiment was repeated three times with 
three replicate wells per cell line.
Western blotting. A detailed procedure has already been published  elsewhere51. Blocking in 3% BSA was 
followed by primary antibody incubation using either mouse anti-V5-tagged Npnt (1:500, Cat: R96025, Invit-
rogen, Carlsbad, CA), or goat anti-integrin subunit α8 (1:800, Cat: AF4076, RD Systems, Minneapolis, MN). 
Secondary antibodies were HRP-linked anti-mouse (1:50,000, Cat: A2554, Sigma Aldrich, St. Louis, MO) and 
HRP-linked anti-goat/sheep (1: 100,000, A9452, Sigma Aldrich, St. Louis, MO). As a control for the anti-integrin 
α8 antibody, homogenized mouse kidney tissue was used as a positive control, while homogenized brain tissue 
was used as a negative control.
For analysis of receptor tyrosine kinase (RTK) phosphorylation, bEND.3 cells were seeded onto either 
rmNPNT- or Pluronic coated wells, and harvested after 0 h, 1 h, 3 h, 5 h and 24 h. The Anti-Phospho-Tyrosine-
HRP Detection Antibody (Cat: 841403, RD Systems, Minneapolis, MN) was diluted 1:5,000 and incubated 
overnight at 4 °C.
Proteome profiler. The bEND.3 cells were seeded onto wells coated with either 2 μg/ml rmNPNT (Cat: 
4298-NP-050, RD Systems, Minneapolis, MN) or 10 mg/ml Pluronic Prill Poloxamer 338 (Cat: F108NF, BASF 
Corp., Florham, NJ) as a negative control for adhesion. Non-adherent cells were harvested by centrifugation 
Table 1.  Immunohistochemical (IHC) methods. Buffers, blocking agent, antigen retrieval methods and 
antibodies used for the different tissues are given together with the figure in which the results can be viewed.
Tissue Figure Protein Primary antibody Antigen retrieval Wash buffer Blocking
MMTV-PyMT/FVB and human 
xenografts Figure 2a, b NPNT
1:150 rabbit anti-human 
NPNT (HPA003711, PRID: 
AB_1854591)
Tris-EDTA pH 9.0 PBS 0.1% Tween 4% goat serum PBS
Human breast cancer brain 
metastasis Figure 1f NPNT
1:50 rabbit anti-human NPNT 
(HPA003711) 10 mM citrate buffer pH 6.0 PBS 4% goat serum PBS
Human breast cancer brain 
metastasis Figure 1g Integrin α8
1:100 rabbit anti-human 
Itgα8 (NBP1-86519, PRID: 
AB_11011205)
Tris-EDTA pH 9.0 PBS 1.5% goat serum PBS
Mouse brain metastasis Figure 4a, b mCherry 1:300 rabbit anti-mCherry (Ab167453, PRID: AB_2571870) Tris-EDTA pH 9.0 PBS 1.5% goat serum PBS
Mouse brain metastasis Figure S4b, c CD31
1:10 rat anti-mouse CD31 
(550274, PRID: AB_393571), 
linker: rabbit anti-rat (E0468, 
Dako)
Enzymatic pepsin digestion 
(1:100) PBS 3% BSA
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and adhered cells were harvested by scraping after three hours. Cells were lysed and analysed using the Pro-
teome Profiler Antibody Array Human Phospho-Kinase Array (Cat: ARY003B, RD Systems, Minneapolis, MN) 
according to the manufacturers’ protocol.
Statistical analysis. Data are presented as mean values ± standard error of mean (SEM). Differences 
between groups were assessed using one-way ANOVA and post-hoc Tukey. p values < 0.05 were accepted as 
statistically significant.
Ethical approval and consent to participate. The Regional Committees for Medical and Health 
Research Ethics (REC; Norway 2010/1523) approved the use of human primary BC samples. Tumour- and 
pair matched normal tissue specimens were collected from 23 women treated at the University Hospital of 
North Norway (UNN) in Tromsø in 2012 as previously  described46. A written informed consent was obtained 
from all subjects and all methods were carried out in accordance with relevant guidelines and regulations. The 
Regional Committees for Medical and Health Research Ethics (REC; Norway 2018/163) approved the use of 
human BC brain metastasis samples. Patients received written information about the study with the option to 
opt out of the study. Formalin fixed, paraffin embedded human BC brain metastasis tissue was retrieved from 
the archives of the University Hospital of North Norway (UNN), Tromsø. Patient information was de-identified 
prior to analysis. Information about BC subtypes was incomplete and is therefore not included. All animal 
experiments were performed according to national and international recommendations for care and use of labo-
ratory animals. Protocols were approved by the local control facilities: Intracarotid injections and isolation of 
endothelial cells; Regional Animal Health and Food Control Station of Csongrád County, Hungary (Permit 
No: XVI./2,980/2012), FVB and MMTV-PyMT experiments; Norwegian Food Safety Authority (FOTS number 
3683), MCF-7, SK-BR-3 and BT474 nu/nu mice xenografts; approved by the Peter MacCallum Animal Experi-
mentation Ethics Committee (Ethics no.: E509). The MCF-7, SK-BR-3 and BT474 xenograft tissues were a kind 
gift from Robin Anderson (Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia) and 
Cameron Johnstone (Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia).
Data availability
The datasets used and analysed during the current study are available from the corresponding author on reason-
able request.
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